Unapproved hydrocodone crackdown
Executive Summary
FDA is allowing manufacturers of unapproved cough-suppressants containing hydrocodone 30 days to cease production of such products labeled for use in children under six years of age before agency begins enforcement actions. Agency officials estimate there are currently 200 unapproved antitussants containing hydrocodone on the market, compared to seven approved products, suggesting that majority of patients are prescribed unapproved drugs. Reported medication errors based on labeling confusion and formulation differences, neither of which FDA can control for unapproved products, warrant priority enforcement, according to CDER Office of Compliance Director Deborah Autor. FDA is taking stronger enforcement measures against unapproved products following a 2006 compliance policy guide (1"The Pink Sheet" June 12, 2006, p. 10)...
You may also be interested in...
FDA Crackdown On Unapproved Drugs Has Incentives For Voluntary Submissions
FDA is encouraging manufacturers of marketed but unapproved drugs to voluntarily submit applications by highlighting the possibility of a de facto exclusivity period for sponsors who receive NDA approval for a drug that other firms are marketing without approval
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.